Life Sciences News Update

Bio.com / Bio Online newsletter at bio.com
Wed May 22 03:13:10 EST 2002

Bio.com Life Sciences News Update
May 22, 2002

Produced by Bio Online®
Portal to the Life Sciences(tm)
www.bio.com | www.bioprotocol.com



1.  Science News: “Molecularly Targeted Drug Slows Tumor Growth”
2.  InFocus:  “Protein Kinases” — hear what the experts have to say
3.  Career Center:  The “Next Generation” Career Center is here
4.  Jobs of the Week:  “Anti-Aging Expert” and others
5.  Featured Employer:  ICOS Corporation
6.  Market Research:  “Fighting Disease with DNA and RNA”
7.  Featured Software:  “Array Designer 2” and others

Newsletter Sponsored by:  IBC USA Conferences

IBC’s Drug Discovery Technology™ 2002: 
The World’s Drug Discovery Meeting Place
August 4-9, 2002 * The Hynes Convention Center * Boston, MA
Your opportunity to learn the latest in drug discovery and 
network with 5,000+ leaders in the field.  
For more information:

**To receive a 10% discount for the Drug Discovery Technology 2002
conference, click here:


-Engineered Anti-Cancer Virus is Potent, Selective
A newly engineered human cold virus is so potent and selective against tumor
cells it may prove to be well suited for systemic treatment of multiple
metastatic cancers. Researchers at Onyx Pharmaceuticals have created a 
virus called ONYX-411 that targets and kills a broad array of human tumor
cell types without harming healthy cells. Their research is presented in the
May issue of Cancer Cell.

-Laser Tweezers Measure Ligand-Receptor Binding
Using "laser tweezers," researchers at the University of Pennsylvania School
of Medicine have measured the strength of the bond between a single integrin
molecule on the surface of a platelet and a molecule of fibrinogen, a
clotting protein found in the bloodstream. These findings refine the current
paradigm of how blood clots form.

-How Ramoplanin Dodges Antibiotic Resistance
In the online early edition of the Proceedings of the National Academy
of Sciences, researchers at the University of Pennsylvania School of
Medicine describe how one antibiotic currently under Phase III clinical
testing, ramoplanin, works on the molecular level to disrupt the ability of
bacteria to build cell walls. The researchers believe that lessons learned
from ramoplanin may aid in developing new classes of antibiotics for
treatment of antimicrobial resistance.

-First Animal Model of Chronic Lymphocytic Leukemia
Researchers at Jefferson Medical College and the Kimmel Cancer Center at
Thomas Jefferson University in Philadelphia have developed the first animal
model of the most common type of human leukemia. The new model should enable
scientists to gain both a better understanding of the biochemical and
molecular mechanisms underlying the disease, chronic lymphocytic leukemia
(CLL), while at the same time provide a testing ground for potential new

-Molecularly Targeted Drug Slows Tumor Growth
Researchers from the National Cancer Institute (NCI) reported today that the
molecularly targeted drug bevacizumab slowed tumor growth in patients with
metastatic renal cell carcinoma, the most common form of kidney cancer in
adults. The findings from their randomized clinical trial were presented at
the American Society for Clinical Oncology meeting in Orlando, Fla.

-New Gene Therapy Technique Using Papilloma Virus
A new technique for introducing genes into mammalian cells using the virus
responsible for warts could be a major step forward in developing gene
therapy treatments. The tehnique has been used for people with familial
hypercholesterolemia (FH), a genetic disease that affects around 12 million
people worldwide.

-FEATURE: The Other Side of Drug Discovery, Part 2
Drug development is the single most regulated human activity, says TSRI
investigator Tamas Bartfai, and the landscape of the approval process is
pock-marked with pitfalls and chasms that can derail a potential drug's
commercial success even after it has emerged as a highly successful
candidate. Communicating how to navigate this landscape is one of Bartfai's
goals for his Skaggs Lectures in Drug Discovery. This is part two in a
two-part series.

-FEATURE: Signs of the Times - The Biotech Century
Biotechnology will change the world more than computers ever have, states
local attorney, bioengineer, and ePrairie contributor Breffni X. Baggot in
his critique of a book on a "second genesis" by Jeremy Rifkin. Breffni X.
Baggot is an attorney and bioengineer (http://bio.io).

To view Industry news, visit:

To view Research news, visit:


1)  "Therapeutic Drug Targets: Protein Kinases"
Broadcast Friday, May 10, 2002

* Click here to view the PDF transcript:

*Click here to listen to the audio recording:

*Click here to enter a drawing for a giveaway from our sponsors:

*For information on how to tune in to Bio.com’s live webcasts, go to:

*To view all past InFocus Webcast recordings and transcripts, go to:


Bio.com announces the “Next Generation” Career Center!

-Over 1,800 biotechnology positions at your fingertips
-New features available making your job search more powerful than ever

Visit us today to set up your FREE personal profile:


Look at what’s new in the Bio.com Career Center this week:

1.  CDI:  Medical Technologist

2.  D.E. Shaw:  Anti-Aging Expert

3.  Cahill & Associates:  Director of BioInformatics

4.  BioNumerik:  Research Assistant

5.  Rosetta Inpharmatics:  Program Lead Scientist, Basic Research

6.  Genitope Corporation:  Molecular Biology Research Assistant/Associate

7.  Genentech:  Scientist

8.  Hyseq:  Scientist

9.  Onyx Pharmaceuticals:  QA Manager

Register today and start using our new features:

Click here to browse all jobs from Bio.com’s Career Center:


ICOS is discovering and developing breakthrough, proprietary products with
high commercial potential for the treatment of serious medical diseases.
We've spent more than a decade building a highly credible, committed
research and development team. Today, with three late-stage products and
more moving steadily through the product pipeline, we are strategically
poised to become a strong and successful commercial organization.
Please view our careers page for current openings:


Bio.com offers the most comprehensive collection of market research.

-Fighting Disease with DNA and RNA
Nucleic acid therapeutics, including antisense, ribozymes, and transcription
factor decoys, are likely to become as large a factor in biotechnology in
the next ten years as monoclonal antibodies are today. Antisense and other
therapeutics made from nucleic acids (RNA or DNA) attack diseases by
interacting with the most fundamental of biological processes. The inherent
specificity and predictability of DNA and RNA interactions exquisitely
targets nucleic acid therapeutics to fundamental molecules responsible for
disease progression. However, their development has encountered many
problems, including the difficulty of getting enough drug to the appropriate

-A Guide to Good Validation Practices
This Guide provides practical advice on compliance with the requirements for
the validation of facility systems, manufacturing processes, and analytical
test methods.  Delays to clinical trial initiation or product approval
resulting from validation non-compliance will adversely affect a company's
cash flow and competitive position. D&MD How-To Guides are hands-on 
practical manuals designed to lead pharmaceutical and biotechnology
professionals through regulatory and business topics.

-Key Medical Membrane Devices for the New Millennium
This BCC technical/market study provides an in-depth analysis of the
relevant technical and economic drivers for the medical membrane device
market by technology type, forecasting growth, and trends in the various
sectors over the next 5 years. The conclusions are illustrated with
important statistical and analytical information on markets, applications,
industry structure, and dynamics, along with technological developments.
This report is intended for those who require a thorough analysis of the
medical membrane device industry that traces significant developments and
forecasts important trends, quantifies the various market sectors and
profiles companies active in those areas.

Click here to browse through our publications catalogue:


Bio.com offers a very comprehensive selection of Life Science related
software. Check out these latest additions:

-Array Designer 2
DNA Microarray Software: Batch PCR primer design and hybridization probe
design tool for Windows.  Supports many specialized needs like ORF studies
and SNP detection using primer extension. Can be used with DNA chip and gene
chip arrays.

-Alchemy 2000
A chemical discovery system for the personal computer with advanced
molecular graphic displays, accurate energy calculations, and customizable
tools that allow you to tailor the program for your research team. Alchemy
2000 delivers high performance visualization with all types of chemical
structures including proteins, polymers, and small molecules. This is a
complete chemical discovery system built on next generation technologies
that is easy to use, comprehensive, and powerful.

The culmination of over 10 years of development, the new Windows version of
PKAnalyst integrates and extends three previous MicroMath products into an
easy-to-use program devoted to pharmacokinetic data fitting.  New features
in PKAnalyst include hypertext-based online help, 3D line and surface
plotting, more intuitive graphics interaction, a more powerful text editor,
and expanded documentation and examples.  The capabilities in the PKAnalyst
editor allow you to prepare technical reports directly within the program
during your current data analysis session - this is especially useful in
view of the new "paperless" submission requirements for many government

Click here to browse through our software catalogue:

This message is sent to <arrays at net.bio.net> per your request
To unsubscribe, simply hit Reply from this email account <arrays at net.bio.net>
and put the word 'unsubscribe' in the subject field.
Copyright © 2002 Bio Online, Inc.  All rights reserved.


More information about the Arrays mailing list

Send comments to us at biosci-help [At] net.bio.net